Advertisement

Surgery pp 1491-1523 | Cite as

Lung Neoplasms

  • Frank C. Detterbeck
  • Scott N. Gettinger
  • Mark A. Socinski

Abstract

Lung cancer is the leading cause of cancer deaths in men and in women in both the United States and the world.1 In fact, lung cancer accounts for more cancer deaths than the next four leading causes of cancer deaths combined (Fig. 71.1). Although the incidence of cancer deaths in men has been decreasing since 1990 and has begun to level off in women, lung cancer will continue to be the leading cause of cancer deaths for at least the next 30 years based on the current trends.2,3

Keywords

Lung Cancer Clin Oncol Small Cell Lung Cancer Natl Cancer Inst Well Supportive Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005. 55:10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown, C.C., and L.G. Kessler. Projections of lung cancer mortality in the United States: 1985–2025. J Natl Cancer Inst 1988. 80:43–51.PubMedCrossRefGoogle Scholar
  3. 3.
    U.S. Department of Health and Human Services. Cigarette smoking among high school students-11 states, 1991–1997. MMWR Morb Mortal Wkly Rep 1998. 48:686–692.Google Scholar
  4. 4.
    Rivera, M.P., F.C. Detterbeck, and D.P. Loomis. Epidemiology and classification of lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:25–44.Google Scholar
  5. 5.
    Flehinger, B.J., M. Kimmel, and M.R. Melamed. The effect of surgical treatment on survival from early lung cancer: implications for screening. Chest 1992. 101:1013–1018.PubMedCrossRefGoogle Scholar
  6. 6.
    Vrdoljak, E., et al. Survival analysis of untreated patients with non-small-cell lung cancer. Chest 1994. 106:1797–1800.PubMedCrossRefGoogle Scholar
  7. 7.
    Kyasa, M.J., and A.R. Jazieh. Characteristics and outcomes of patients with unresected early-stage non-small cell lung cancer. South Med J 2002. 95:1149–1152.PubMedGoogle Scholar
  8. 8.
    Fry, W.A., H.R. Menck, and D.P. Winchester. The National Cancer Data Base report on lung cancer. Cancer 1996. 77:1947–1955.PubMedCrossRefGoogle Scholar
  9. 9.
    Bach, P.B., et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999. 341:1198–1205.PubMedCrossRefGoogle Scholar
  10. 10.
    Potosky, A.L., et al. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004. 22:3261–3268.PubMedCrossRefGoogle Scholar
  11. 11.
    Janssen-Heijnen, M.L., et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004. 59:602–607.PubMedCrossRefGoogle Scholar
  12. 12.
    Ramsey, S.D., et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results–Medicare. J Clin Oncol 2004. 22:4971–4978.PubMedCrossRefGoogle Scholar
  13. 13.
    Visbal, A.L., et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004. 78:209–215; discussion 215.PubMedCrossRefGoogle Scholar
  14. 14.
    Garces, Y.I., et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004. 126:1733–1741.PubMedCrossRefGoogle Scholar
  15. 15.
    Tong, L., et al. Lung carcinoma in former smokers. Cancer 1996. 78:1004–1010.PubMedCrossRefGoogle Scholar
  16. 16.
    Centers for Disease Control. Public Health Service, U.S. Department of Health and Human Services, The health benefits of smoking cessation. DHHS Publication No. (CDC)90-8416. Washington, DC: U.S. Government Printing Office.Google Scholar
  17. 17.
    Halpern, M.T., B.W. Gillespie, and K.E. Warner. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993. 85:457–464.PubMedCrossRefGoogle Scholar
  18. 18.
    Ikeda, N., et al. A clinicopathological study of resected adenocarcinoma 2 cm or less in diameter. Ann Thorac Surg 2004. 78:1011–1016.PubMedCrossRefGoogle Scholar
  19. 19.
    Ebright, M.I., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002. 74:1640–1647.PubMedCrossRefGoogle Scholar
  20. 20.
    Mountain, C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997. 111:1710–1717.PubMedCrossRefGoogle Scholar
  21. 21.
    Janssen-Heijnen, M.L.G., et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998. 21:105–113.PubMedCrossRefGoogle Scholar
  22. 22.
    Malmberg, R., et al. Lung cancer in West Sweden 1976–1985. Acta Oncologica 1996. 35:185–192.PubMedCrossRefGoogle Scholar
  23. 23.
    Detterbeck, F.C., and M.P. Rivera. Clinical presentation and diagnosis, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:45–72.Google Scholar
  24. 24.
    Fang, D., et al. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1905 cases. Ann Thorac Surg 2001. 72:1155–1159.PubMedCrossRefGoogle Scholar
  25. 25.
    Chute, C.G., et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985. 56:2107–2111.PubMedCrossRefGoogle Scholar
  26. 26.
    Huhti, E., et al. Lung cancer in a defined geographical area: history and histological types. Thorax 1980. 35:660–667.PubMedCrossRefGoogle Scholar
  27. 27.
    Ferguson, M.K. Diagnosing and staging of non-small cell lung cancer. Hematol/Oncol Clin N Am 1990. 4:1053–1068.Google Scholar
  28. 28.
    Bülzebruck, H., et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992. 70:1102–1110.PubMedCrossRefGoogle Scholar
  29. 29.
    Byers, T.E., J.E. Vena, and T.F. Rzepka. Predilection of lung cancer for the upper lobes: an epidemiologic inquiry. J Natl Cancer Inst 1984. 72:1271–1275.PubMedGoogle Scholar
  30. 30.
    Quinn, D., A. Gianlupi, and S. Broste. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest 1996. 110:1474–1479.PubMedCrossRefGoogle Scholar
  31. 31.
    Quekel, L.G.B.A., et al. Miss rate of lung cancer on the chest radiograph in clinical practice. Chest 1999. 115:720–724.PubMedCrossRefGoogle Scholar
  32. 32.
    Detterbeck, F.C., D.R. Jones, and W.K. Funkhouser Jr. Satellite nodules and multiple primary cancers, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:437–449.Google Scholar
  33. 33.
    Detterbeck, F., et al. Seeking a home for a PET, Part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004. 125:2294–2299.PubMedCrossRefGoogle Scholar
  34. 34.
    Detterbeck, F.C., D.R. Jones, and P.L. Molina. Extrathoracic staging, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al, eds. Philadelphia: Saunders; 2001:94–110.Google Scholar
  35. 35.
    Detterbeck, F., et al. Seeking a home for a PET, Part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004. 125:2300–2308.PubMedCrossRefGoogle Scholar
  36. 36.
    Rivera, M.P., F. Detterbeck, and A.C. Mehta. Diagnosis of lung cancer: the guidelines. Chest 2003. 123:129S–136S.PubMedCrossRefGoogle Scholar
  37. 37.
    Patchell, R.A., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990. 322:494–500.PubMedGoogle Scholar
  38. 38.
    Jacobson, A.F., et al. Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990. 175:229–232.PubMedGoogle Scholar
  39. 39.
    Ichinose, Y., et al. Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer: preoperative examination for lung cancer. Chest 1989. 96:1104–1109.PubMedCrossRefGoogle Scholar
  40. 40.
    Grant, D.; D. Edwards, and P. Goldstraw. Computed tomography of the brain, chest, and abdomen in the postoperative assessment of non-small cell lung cancer. Thorax 1988. 43:883–886.PubMedCrossRefGoogle Scholar
  41. 41.
    MacManus, M.P., et al. High rate of detection of unsuspected distant metastases by PET in apparent stage IE non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiation Oncology Biol Phys 2001. 50:287–293.CrossRefGoogle Scholar
  42. 42.
    Weder, W., et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998. 66:886–893.PubMedCrossRefGoogle Scholar
  43. 43.
    Viney, R.C., et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004. 22:2357–2362.PubMedCrossRefGoogle Scholar
  44. 44.
    Reed, C., et al. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003. 126:1943–1951.PubMedCrossRefGoogle Scholar
  45. 45.
    Farrell, M.A., et al. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000. 215:886–890.PubMedGoogle Scholar
  46. 46.
    Salvatierra, A., et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990. 97:1052–1058.PubMedCrossRefGoogle Scholar
  47. 47.
    Quinn, D.L., et al. Staging of non-small cell bronchogenic carcinoma: relationship of the clinical evaluation to organ scans. Chest 1986. 89:270–275.PubMedCrossRefGoogle Scholar
  48. 48.
    Eschmann, S.M., et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002. 29:804–808.PubMedCrossRefGoogle Scholar
  49. 49.
    Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer: update of Cancer and Leukemia Group B protocol 9633. J Clin Oncol 2006 ASCO Ann Mtg Proc 2006;24(18S):7007.Google Scholar
  50. 50.
    Birim, O., et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005. 79:375–382.PubMedCrossRefGoogle Scholar
  51. 51.
    Detterbeck, F.C., et al. Invasive staging: the guidelines. Chest 2003. 123:167S–175S.PubMedCrossRefGoogle Scholar
  52. 52.
    Silvestri, G.A., et al. The noninvasive staging of non-small cell lung cancer. Chest 2003. 123:147S–156S.PubMedCrossRefGoogle Scholar
  53. 53.
    Detterbeck, F.C., D.R. Jones, and L.A. Parker Jr. Intrathoracic staging, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:73–93.Google Scholar
  54. 54.
    Verhagen, A.F.T., et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004. 44:175–181.PubMedCrossRefGoogle Scholar
  55. 55.
    Serra, M., et al. Routine positron tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC). J Clin Oncol 2006. 24(18S), pt 1 of II:371s.Google Scholar
  56. 56.
    Gould, M.K., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003. 139:879–892.PubMedGoogle Scholar
  57. 57.
    Dietlein, M., et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer; priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000. 27:1598–1609.PubMedCrossRefGoogle Scholar
  58. 58.
    Toloza, E.M., et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003. 123:157S–166S.PubMedCrossRefGoogle Scholar
  59. 59.
    Rolston, K.V.I., et al. Pulmonary infections mimicking cancer: a retrospective, 3-year review. Support Care Cancer 1997. 5:90–93.PubMedCrossRefGoogle Scholar
  60. 60.
    Jones, D.R., and F.C. Detterbeck. Surgery for stage I non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:177–190.Google Scholar
  61. 61.
    Handy, J.R., Jr., et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest 2002. 122:21–30.PubMedCrossRefGoogle Scholar
  62. 62.
    Allen, M.S., et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 Trial 10.1016/j.athoracsur.2005.06.066. Ann Thorac Surg 2006. 81:1013–1020.PubMedCrossRefGoogle Scholar
  63. 63.
    McKenna, R.J., Jr., et al. Video-assisted thoracic surgery (VATS) lobectomy for bronchogenic carcinoma. Semin Thorac Cardiovasc Surg 1998. 10:321–325.PubMedGoogle Scholar
  64. 64.
    Kaseda, S., T. Aoki, and N. Hangai. Video-assisted thoracic surgery (VATS) lobectomy: the Japanese experience. Semin Thorac Cardiovasc Surg 1998. 10:300–304.PubMedGoogle Scholar
  65. 65.
    Walker, W.S. Video-assisted thoracic surgery (VATS) lobectomy: the Edinburgh experience. Semin Thorac Cardiovasc Surg 1998. 10:291–299.PubMedGoogle Scholar
  66. 66.
    Iwasaki, A., et al. Results of video-assisted thoracic surgery for stage I/II non-small cell lung cancer. Eur J Cardiothorac Surg 2004. 26:158–164.PubMedCrossRefGoogle Scholar
  67. 67.
    Solaini, L., et al. Long-term results of video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer: a single-centre study of 104 cases. Interact Cardiovasc Thorac Surg 2004. 3:57–62.PubMedCrossRefGoogle Scholar
  68. 68.
    Roviaro, G., et al. Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest 2004. 126:725–732.PubMedCrossRefGoogle Scholar
  69. 69.
    Thomas, P., et al. Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection. Ann Thorac Surg 2002. 73:1065–1070.PubMedCrossRefGoogle Scholar
  70. 70.
    Detterbeck, F.C., and T.M. Egan. Surgery for stage II non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:191–197.Google Scholar
  71. 71.
    Van Schil, P.E., et al. TNM staging and long-term follow-up after sleeve resection for bronchogenic tumors. Ann Thorac Surg 1991. 52:1096–1101.PubMedCrossRefGoogle Scholar
  72. 72.
    Okada, M., et al. Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy. J Thorac Cardiovasc Surg 2000. 119:814–819.PubMedCrossRefGoogle Scholar
  73. 73.
    Detterbeck, F.C., and D.R. Jones. Surgery for stage nib non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:283–289.Google Scholar
  74. 74.
    Detterbeck, F.C., and A.C. Kiser. T3 non-small cell lung cancer (stage IIb-IIIa), in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:223–232.Google Scholar
  75. 75.
    Smythe, W.R. Treatment of stage I non-small cell lung carcinoma. Chest 2003. 123(1 suppl):181S–187S.PubMedCrossRefGoogle Scholar
  76. 76.
    Bollen, E.C.M., et al. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg 1993. 55:961–966.PubMedCrossRefGoogle Scholar
  77. 77.
    Gaer, J.A.R., and P. Goldstraw. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus. Eur J Cardiothorac Surg, 1990. 4:207–210.PubMedCrossRefGoogle Scholar
  78. 78.
    Wu, Y., et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002. 36:1–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Izbicki, J.R., et al. Impact on radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg 1995. 59:209–214.PubMedCrossRefGoogle Scholar
  80. 80.
    Kiser, A.C., and F.C. Detterbeck. General aspects of surgical treatment, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:133–147.Google Scholar
  81. 81.
    Silvestri, G.A., et al. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998. 114:675–680.PubMedCrossRefGoogle Scholar
  82. 82.
    Romano, P.S., and D.H. Mark. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992. 101:1332–1337.PubMedCrossRefGoogle Scholar
  83. 83.
    Hillner, B.E., T.J. Smith, and C.E. Desch. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000. 18:2327–40.PubMedGoogle Scholar
  84. 84.
    Begg, C.B., et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA, 1998. 280:1747–1751.PubMedCrossRefGoogle Scholar
  85. 85.
    Birkmeyer, J.D., et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003. 349:2117–2127.PubMedCrossRefGoogle Scholar
  86. 86.
    Martinolich, D., and M.P. Rivera. Pulmonary assessment and treatment, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:113–132.Google Scholar
  87. 87.
    Kohman, L.J., et al., Random versus predictable risks of mortality after thoracotomy for lung cancer. J Thorac Cardiovasc Surg 1986. 91:551–554.PubMedGoogle Scholar
  88. 88.
    Lopez-Encuentra, A., et al. Surgical lung cancer. Risk operative analysis. Lung Cancer 2004. 44:327–337.PubMedCrossRefGoogle Scholar
  89. 89.
    Wang, J., et al. Assessment of pulmonary complications after lung resection. Ann Thorac Surg 1999. 67:1444–1447.PubMedCrossRefGoogle Scholar
  90. 90.
    Boysen, P.G., J.O. Harris, and A.J. Block. Prospective evaluation for pneumonectomy using perfusion scanning: follow-up beyond 1 year. Chest 1981. 80:163–166.PubMedCrossRefGoogle Scholar
  91. 91.
    Dales, R.E., et al. Quality-of-life following thoracotomy for lung cancer. J Clin Epidemiol 1994. 47:1443–1449.PubMedCrossRefGoogle Scholar
  92. 92.
    Zieren, H.U., et al. Quality of life after surgical therapy of bronchogenic carcinoma. Eur J Cardiothorac Surg 1996. 10:233–237.PubMedCrossRefGoogle Scholar
  93. 93.
    Myrdal, G., et al. Quality of life following lung cancer surgery. Thorax 2003. 58:194–197.PubMedCrossRefGoogle Scholar
  94. 94.
    Markos, J., et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989. 139:902–910.PubMedGoogle Scholar
  95. 95.
    Holden, D.A., T.W. Rice, and K. Stelmach. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest 1992. 102:1774–1779.PubMedCrossRefGoogle Scholar
  96. 96.
    Pierce, R., et al. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 1994. 150:947–955.PubMedGoogle Scholar
  97. 97.
    Wahi, R., et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 1989. 48:33–37.PubMedCrossRefGoogle Scholar
  98. 98.
    Nakagawa, K., K. Nakahara, and S. Miyoshi. Oxygen transport during incremental exercise load as a predictor of operative risk in lung cancer patients. Chest 1992. 101:1369–1375.PubMedCrossRefGoogle Scholar
  99. 99.
    Nakahara, K., et al. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg 1985. 39:260–265.PubMedCrossRefGoogle Scholar
  100. 100.
    Bolliger, C.T., et al. Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest 1995. 108:341–348.PubMedCrossRefGoogle Scholar
  101. 101.
    Bolliger, C.T., P. Jordan, and M. Soler. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med 1995. 151:1472–1480.PubMedGoogle Scholar
  102. 102.
    Bechard, D., and L. Wetstein. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. Ann Thorac Surg 1987. 44:344–349.PubMedCrossRefGoogle Scholar
  103. 103.
    Smith, T.P., et al. Exercise capacity as a predictor of post-thoracotomy morbidity. Am Rev Respir Dis 1984. 129:730–734.PubMedGoogle Scholar
  104. 104.
    Martini, N., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995. 109:120–129.PubMedCrossRefGoogle Scholar
  105. 105.
    Padilla, J., et al. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997. 63:324–326.PubMedCrossRefGoogle Scholar
  106. 106.
    Sobue, T., et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002. 20:911–920.PubMedCrossRefGoogle Scholar
  107. 107.
    Okada, M., et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004. 78:216–221.PubMedCrossRefGoogle Scholar
  108. 108.
    Patz, E.F., Jr., et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000. 117:1568–1571.PubMedCrossRefGoogle Scholar
  109. 109.
    Padilla, J., et al. Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002. 36:43–48.PubMedCrossRefGoogle Scholar
  110. 110.
    Ichinose, Y., et al. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer: an analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995. 110:601–605.PubMedCrossRefGoogle Scholar
  111. 111.
    Takizawa, T., et al. Lymph node metastasis in small peripheral adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1998. 116:276–280.PubMedCrossRefGoogle Scholar
  112. 112.
    Harpole, D.H., Jr., et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995. 76:787–796.PubMedCrossRefGoogle Scholar
  113. 113.
    Chung, C.K., et al. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg 1982. 33:599–604.PubMedCrossRefGoogle Scholar
  114. 114.
    Martini, N., et al. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg 1992. 54:460–466.PubMedCrossRefGoogle Scholar
  115. 115.
    Osaki, T., et al. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 2004. 43:151–157.PubMedCrossRefGoogle Scholar
  116. 116.
    Marra, A., et al. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2003. 125:543–553.PubMedCrossRefGoogle Scholar
  117. 117.
    Yano, T., et al. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung-significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg 1994. 107:1398–1402.PubMedGoogle Scholar
  118. 118.
    van Velzen, E., et al. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Chest 1996. 110:1469–1473.PubMedCrossRefGoogle Scholar
  119. 119.
    Riquet, M., et al. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg 1999. 67:1572–1576.PubMedCrossRefGoogle Scholar
  120. 120.
    Sawyer, T.E., et al. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg 1999. 68:1171–1176.PubMedCrossRefGoogle Scholar
  121. 121.
    van Velzen, E., et al. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg 1997. 63:1436–1440.PubMedCrossRefGoogle Scholar
  122. 122.
    Yoshino, I., et al. Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases. Chest 1999. 116:144–149.PubMedCrossRefGoogle Scholar
  123. 123.
    Tanaka, F., et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 2001. 19:555–561.PubMedCrossRefGoogle Scholar
  124. 124.
    Khan, O.A., et al. Histological determinants of survival in completely resected T1-2N1M0 nonsmall cell cancer of the lung. Ann Thorac Surg 2004. 77:1173–1178.PubMedCrossRefGoogle Scholar
  125. 125.
    Luzzi, L., et al. Pneumonectomy versus lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J Cardiovasc Surg 2003. 44:119–123.Google Scholar
  126. 126.
    Iyengar, P., and M.S. Tsao. Clinical relevance of molecular markers in lung cancer. Surg Oncol 2002. 11:167–179.PubMedCrossRefGoogle Scholar
  127. 127.
    Rena, O., et al. Stage I non-small cell lung carcinoma: really an early stage? Eur J Cardiothorac Surg 2002. 21:514–519.PubMedCrossRefGoogle Scholar
  128. 128.
    Keller, S.M., et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer; from the Eastern Cooperative Oncology Group. Ann Thorac Surg 2000. 70:358–365.PubMedCrossRefGoogle Scholar
  129. 129.
    Sugi, K., et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg 1998. 22:290–294.PubMedCrossRefGoogle Scholar
  130. 130.
    Izbicki, J.R., et al. Radical systematic mediastinal lymphadenec-tomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg 1994. 81:229–235.PubMedCrossRefGoogle Scholar
  131. 131.
    Funatsu, T., et al. Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer. J Thorac Cardiovasc Surg 1994. 108:321–328.PubMedGoogle Scholar
  132. 132.
    Martin-Ucar, A.E., et al. Can pneumonectomy for non-small cell lung cancer be avoided? An audit of parenchymal sparing lung surgery. Eur J Cardiothorac Surg 2002. 21:601–605.PubMedCrossRefGoogle Scholar
  133. 133.
    Deslauriers, J., et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004. 77:1152–1156; discussion 1156.PubMedCrossRefGoogle Scholar
  134. 134.
    Kaiser, L.R., et al. Significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg 1989. 47:265–269.PubMedGoogle Scholar
  135. 135.
    Gaissert, H.A., et al. Survival and function after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg 1996. 111:948–953.PubMedCrossRefGoogle Scholar
  136. 136.
    Naruke, T. Bronchoplastic and bronchovascular procedures of the tracheobronchial tree in the management of primary lung cancer. Chest 1989. 96:53S–56S.PubMedCrossRefGoogle Scholar
  137. 137.
    Vogt-Moykopf, I., et al. Bronchoplastic and angioplastic operation in bronchial carcinoma: long-term results of a retrospective analysis from 1973 to 1983. Intern Surg 1986. 71:211–220.Google Scholar
  138. 138.
    Rendina, E.A., F. Venuta, and T. De Giacomo. Sleeve resection and prosthetic reconstruction of the pulmonary artery for lung cancer. Ann Thorac Surg 1999. 68:995–1002.PubMedCrossRefGoogle Scholar
  139. 139.
    Ginsberg, R.J., L.V. Rubinstein, and the Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995. 60:615–623.PubMedCrossRefGoogle Scholar
  140. 140.
    Rubinstein, L.V., and R.J. Ginsberg. Reply to “Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer,” 1995 article by the Lung Cancer Study Group. Ann Thorac Surg 1996. 62:1249–1250.CrossRefGoogle Scholar
  141. 141.
    Warren, W.H., and L.P. Faber. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. J Thorac Cardiovasc Surg 1994. 107:1087–1094.PubMedGoogle Scholar
  142. 142.
    Strauss, G., et al. Extent of surgical resection influences survival in stage LA non-small cell lung cancer (NSCLC). Proc ASCO, 1998. 17:462a.Google Scholar
  143. 143.
    Landreneau, R.J., et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997. 113:691–700.PubMedCrossRefGoogle Scholar
  144. 144.
    Errett, L.E., et al. Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients. J Thorac Cardiovasc Surg 1985. 90:656–661.PubMedGoogle Scholar
  145. 145.
    Pastorino, U., et al. Limited resection for stage I lung cancer. Eur J Surg Oncol 1991. 17:42–46.PubMedGoogle Scholar
  146. 146.
    Kodama, K., et al. Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg 1997. 114:347–353.PubMedCrossRefGoogle Scholar
  147. 147.
    Crabbe, M.M., G.A. Patrissi, and L.J. Fontenelle. Minimal resection for bronchogenic carcinoma: should this be standard therapy? Chest 1989. 95:968–971.PubMedCrossRefGoogle Scholar
  148. 148.
    Yano, T., et al. Results of a limited resection for compromised or poor-risk patients with clinical stage I non-small cell carcinoma of the lung. J Am Coll Surg 1995. 181:33–37.PubMedGoogle Scholar
  149. 149.
    Miller, J.I., and C.R. Hatcher Jr. Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg 1987. 44:340–343.PubMedCrossRefGoogle Scholar
  150. 150.
    Jensik, R.J. The extent of resection for localized lung cancer: segmental resection, in Current Controversies in Thoracic Surgery, C.F. Kittle, ed. Philadelphia: Saunders; 1986:175–182.Google Scholar
  151. 151.
    Detterbeck, F.C., D.R. Jones, and W.K. Funkhouser Jr. Bronchio-loalveolar carcinoma, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:394–407.Google Scholar
  152. 152.
    Sakao, Y., et al. Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg 2004. 77:1157–1161; discussion 1161–1162.PubMedCrossRefGoogle Scholar
  153. 153.
    Kondo, T., et al. Radiologic-prognostic correlation in patients with small pulmonary adenocarcinomas. Lung Cancer 2002. 36:49–57.PubMedCrossRefGoogle Scholar
  154. 154.
    Matsuguma, H., et al. Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung. Eur J Cardiothorac Surg 2004. 25:1102–1106.PubMedCrossRefGoogle Scholar
  155. 155.
    Yoshida, J., et al. Limited resection trial for pulmonary ground-glass opacity nodules: 50-case experience. J Thorac Cardiovasc Surg 2005. 129:991–996.PubMedCrossRefGoogle Scholar
  156. 156.
    Suzuki, K., et al. Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg 2001. 72:352–356.PubMedCrossRefGoogle Scholar
  157. 157.
    Koike, T., et al. Clinical analysis of small-sized peripheral lung cancer. J Thorac Cardiovasc Surg 1998. 115:1015–1020.PubMedCrossRefGoogle Scholar
  158. 158.
    Johnson, H., and J.S. Halle. Radiotherapy for stage I, II non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:198–205.Google Scholar
  159. 159.
    Gauden, S., J. Ramsay, and L. Tripcony. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995. 108:1278–1282.PubMedCrossRefGoogle Scholar
  160. 160.
    Morita, K., et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997. 42:31–36.PubMedCrossRefGoogle Scholar
  161. 161.
    Sibley, G.S., et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiation Oncology Biol Phys 1998. 40:149–154.CrossRefGoogle Scholar
  162. 162.
    Krol, A.D.G., et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 1996. 34:297–302.PubMedGoogle Scholar
  163. 163.
    Graham, P.H., V.J. Gebski, and A.O. Langlands. Radical radiotherapy for early nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994. 31:261–266.Google Scholar
  164. 164.
    Sandler, H.M., W.J. Curran Jr., and A.T. Turrisi III. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1990. 19:9–13.PubMedGoogle Scholar
  165. 165.
    Kaskowitz, L., et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993. 27:517–523.PubMedGoogle Scholar
  166. 166.
    Hayakawa, K., et al. High-dose radiation therapy for inoperable non-small cell lung cancer without mediastinal involvement (clinical stage N0, N1). Strahlenther Onkol 1996. 172:489–495.PubMedGoogle Scholar
  167. 167.
    Jeremic, B., et al. Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. Radiother Oncol 1999. 51:141–145.PubMedCrossRefGoogle Scholar
  168. 168.
    Rosenthal, S.A., et al. Clinical stage II non-small cell lung cancer treated with radiation therapy alone: the significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer 1992. 70:2410–2417.PubMedCrossRefGoogle Scholar
  169. 169.
    Noordijk, E.M., et al. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988. 13:83–89.PubMedCrossRefGoogle Scholar
  170. 170.
    Dosoretz, D.E., et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992. 24:3–9.PubMedGoogle Scholar
  171. 171.
    Jeremic, B., et al. Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1997. 38:521–525.PubMedGoogle Scholar
  172. 172.
    Dautzenberg, B., et al., and the Groupe d’Etude et de Traitement des Cancers Bronchiques. A controlled study of postoperative radiotherapy for patients with complete resected nonsmall cell lung carcinoma. Cancer 1999. 86:265–273.PubMedCrossRefGoogle Scholar
  173. 173.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998. 352:257–263.CrossRefGoogle Scholar
  174. 174.
    Sawyer, T.E., et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997. 64:1402–1408.PubMedCrossRefGoogle Scholar
  175. 175.
    Stephens, R.J., et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 1996. 74:632–639.PubMedGoogle Scholar
  176. 176.
    Socinski, M.A., F.C. Detterbeck, and J.G. Rosenman. Adjuvant therapy of resected non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:206–219.Google Scholar
  177. 177.
    Sedrakyan, A., et al. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004. 128:414–419.PubMedCrossRefGoogle Scholar
  178. 178.
    Winton, T.L., et al. A prospective randomised trial of adjuvant venorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR. 10 [abstract].J Clin Oncol 2004 ASCO Annu Mtg Proc 2004. 22(14S):7018.Google Scholar
  179. 179.
    Douillard, J., Rosell, R, Delena, M, et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Proc Am Soc Clin Oncol 2004. 23:615a.Google Scholar
  180. 180.
    Strauss, G.M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage 1B non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. J Clin Oncol 2004 ASCO Annu Mtg Proc 2004. 22(14S):7019.Google Scholar
  181. 181.
    Scott, W.J., J. Howington, S. Feigenberg, et al. Treatment of Non-small Cell Lung Cancer-Stage I and II: ACCP Evidence-Based Clinical Practice Guideline. 2nd ed. Chest 2007;132:234–242.CrossRefGoogle Scholar
  182. 182.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992. 339:71–85.Google Scholar
  183. 183.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995. 356:939–944.Google Scholar
  184. 184.
    Hotta, K., et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004. 22:3860–3867.PubMedCrossRefGoogle Scholar
  185. 185.
    Keicho, N., et al. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986. 16:143–146.PubMedGoogle Scholar
  186. 186.
    Pisters, K.M.W., et al., Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000. 119:429–439.PubMedCrossRefGoogle Scholar
  187. 187.
    Pisters K.V., P. Bunn, et al. S9900: a phase in trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. ASCO Mtg Abstracts 2005. June 1:7012.Google Scholar
  188. 188.
    Depierre, A., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (exept T1N0), II, and Ilia non-small-cell lung cancer. J Clin Oncol 2002. 20:247–253.PubMedCrossRefGoogle Scholar
  189. 189.
    Detterbeck, F.C., and D.R. Jones. Surgical treatment of stage IIIa (N2) non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., edis. Philadelphia: Saunders; 2001:244–256.Google Scholar
  190. 190.
    Cybulsky, I.J., et al. Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg 1992. 54:533–537.PubMedGoogle Scholar
  191. 191.
    Maggi, G., et al. Results of surgical resection of Stage IIIA (N2) non small cell lung cancer, according to the site of the mediastinal metastases. Intern Surg 1993. 78:213–217.Google Scholar
  192. 192.
    Mountain, C.F. Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 1994. 73:2589–2598.PubMedCrossRefGoogle Scholar
  193. 193.
    Goldstraw, P., et al. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994. 107:19–28.PubMedGoogle Scholar
  194. 194.
    Daly, B.D.T., et al. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 1993. 105:904–911.PubMedGoogle Scholar
  195. 195.
    Coughlin, M., et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg 1985. 40:556–560.PubMedCrossRefGoogle Scholar
  196. 196.
    Pearson, F.G., et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982. 83:1–11.PubMedGoogle Scholar
  197. 197.
    Vansteenkiste, J.F., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997. 63:1441–1450.PubMedCrossRefGoogle Scholar
  198. 198.
    Jett, J.R., et al. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003. 123(1 suppl):221S–225S.PubMedCrossRefGoogle Scholar
  199. 199.
    Detterbeck, F.C., et al. Special treatment issues. Chest 2003. 123:244S–258S.PubMedCrossRefGoogle Scholar
  200. 200.
    Tsuchiya, R., et al. Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 1994. 57:960–965.PubMedCrossRefGoogle Scholar
  201. 201.
    de Perrot, M., et al. Long-term results after carinal resection for carcinoma: does the benefit warrant the risk? J Thorac Cardiovasc Surg 2006. 131:81–89.PubMedCrossRefGoogle Scholar
  202. 202.
    Rendina, E.A., et al. Induction chemotherapy for T4 centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg 1999. 117:225–233.PubMedCrossRefGoogle Scholar
  203. 203.
    Hensing, T.A., J.S. Halle, and M.A. Socinki. Chemoradiotherapy for stage IIIa,b non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:291–303.Google Scholar
  204. 204.
    Albain, K.S., et al. Concurrent cisplatin/etoposide plus radiotherapy (PE + RT) for pathologic stage (pathTN) IIIB non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) phase II study (S9019) [abstract]. Proc ASCO 1997. 16:446a.Google Scholar
  205. 205.
    Detterbeck, F.C. Changes in the treatment of Pancoast tumors. Ann Thorac Surg 2003. 75:1990–1997.PubMedCrossRefGoogle Scholar
  206. 206.
    Macchiarini, P. Resection of superior sulcus carcinomas (anterior approach). Thorac Surg Clin 2004. 14:229–240.PubMedCrossRefGoogle Scholar
  207. 207.
    Rusch, V.W., et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Inter-group Trial 0160). J Thorac Cardiovasc Surg 2001. 121:472–483.PubMedCrossRefGoogle Scholar
  208. 208.
    Wright, CD., et al. Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. Ann Thorac Surg 2002. 73:1541–1544.PubMedCrossRefGoogle Scholar
  209. 209.
    Detterbeck, F.C. Pancoast (superior sulcus) tumors. Ann Thorac Surg 1997. 63:1810–1818.PubMedCrossRefGoogle Scholar
  210. 210.
    Ginsberg, R.J., et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg 1994. 57:1440–1445.PubMedCrossRefGoogle Scholar
  211. 211.
    Dillman, R.O., et al. Improved survival in stage HI non-small-cell lung cancer: 7-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996. 88:1210–1215.PubMedCrossRefGoogle Scholar
  212. 212.
    The Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995. 311:899–909.Google Scholar
  213. 213.
    Marino, P., A. Preatoni, and A. Cantoni. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in Stages Ilia and nib nonsmall cell lung cancer: a metaanalysis. Cancer 1995. 76:593–601.PubMedCrossRefGoogle Scholar
  214. 214.
    Furuse, K., et al. and for the West Japan Lung Cancer Group, Phase HI study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cispla-tin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999. 17:2692–2699.PubMedGoogle Scholar
  215. 215.
    Curran, W.J., et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III non small cell lung cancer: RTOG 9410. Proc Am Soc Clin Oncol 2003. 22:621a.Google Scholar
  216. 216.
    Detterbeck, F.C, and M.A. Socinski. Induction therapy and surgery for I-IIIa,b non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:257–266.Google Scholar
  217. 217.
    Siegenthaler, M.P., et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001. 71:1105–1112.PubMedCrossRefGoogle Scholar
  218. 218.
    Veronesi, G., et al. Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer. Lung Cancer 2002. 36:91–97.PubMedCrossRefGoogle Scholar
  219. 219.
    Novoa, N., G. Varela, and M. Jimenez. Morbidity after surgery for non small cell lung carcinoma is not related to neoadjuvant chemotherapy. Eur J Cardiothorac Surg 2001. 20:700–704.PubMedCrossRefGoogle Scholar
  220. 220.
    Rosell, R., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994. 330:153–158.PubMedCrossRefGoogle Scholar
  221. 221.
    Roth, J.A., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994. 86:673–680.PubMedCrossRefGoogle Scholar
  222. 222.
    Wagner, H., Jr., S. Piantadosi, and J.C. Ruckdeschel. Randomized phase II evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cispla-tin in patients with technically unresectable stage IIIA and EQB non-small cell cancer of the lung (Lung Cancer Study Group 881). Chest 1994. 106(suppl):348S–354S.PubMedCrossRefGoogle Scholar
  223. 223.
    Sonett, J.R., et al. Pulmonary resection after curative intent radiotherapy (>59Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004. 78:1200–1205; discussion 1206.PubMedCrossRefGoogle Scholar
  224. 224.
    Roberts, J., et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thor Surg, 2001. 72:885–888.CrossRefGoogle Scholar
  225. 225.
    Semik, M., et al. Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage HI non-small cell lung cancer. Eur J Cardiothorac Surg 2004. 26:1205–1210.PubMedCrossRefGoogle Scholar
  226. 226.
    West, H and Albain, K. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. Semin Oncol 2005. 32:284–292.PubMedCrossRefGoogle Scholar
  227. 227.
    Perez, C.A., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 1980. 45:2744–2753.PubMedCrossRefGoogle Scholar
  228. 228.
    Perez, C.A., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987. 59:1874–1881.PubMedCrossRefGoogle Scholar
  229. 229.
    Arriagada, R., et al. ASTRO Plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991. 20:1183–1190.PubMedGoogle Scholar
  230. 230.
    Clark, J.A., J.G. Rosenman, and F.C. Detterbeck. Radiotherapy alone for stage IHa,b non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:257–266.Google Scholar
  231. 231.
    Rosenman, J.G., et al. Image registration: an essential part of radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 1998. 40:197–205.PubMedCrossRefGoogle Scholar
  232. 232.
    Rosenman, J., M.B. Hazuka, and M.K. Martel. Three-dimensional treatment planning in lung cancer radiotherapy, in Lung Cancer: Principles and Practice, Pass, H.I., ed. Philadelphia: Lippincott-Raven; 1996:685–696.Google Scholar
  233. 233.
    Saunders, M., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 1999. 52:137–148.PubMedCrossRefGoogle Scholar
  234. 234.
    Saunders, M., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 1997. 350:161–165.PubMedCrossRefGoogle Scholar
  235. 235.
    Belani, C.P., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer 10.1200/ JCO.2005.09.108. J Clin Oncol 2005. 23:3760–3767.PubMedCrossRefGoogle Scholar
  236. 236.
    Komaki, R., et al. Induction cisplatin/vinblastine and irradiation versus irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997. 39:537–544.PubMedGoogle Scholar
  237. 237.
    Sause, W., et al. Final results of phase in trial in regionally advanced unresectable non-small cell lung cancer (Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group). Chest 2000. 117:358–364.PubMedCrossRefGoogle Scholar
  238. 238.
    Socinski, M.A., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/pacli-taxel in unresectable stage IILA/B nonsmall cell lung carcinoma. Cancer 2001. 92:1213–1223.PubMedCrossRefGoogle Scholar
  239. 239.
    Socinski, M.A., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004. 22:4341–4350.PubMedCrossRefGoogle Scholar
  240. 240.
    Miller, K.L., et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 2005. 61:64–69.PubMedGoogle Scholar
  241. 241.
    Marks, L.B., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 2004. 22:4329–4340.PubMedCrossRefGoogle Scholar
  242. 242.
    Hayman, J.A., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001. 19:127–136.PubMedGoogle Scholar
  243. 243.
    Wu, K.-L., et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003. 57:1336–1344.PubMedGoogle Scholar
  244. 244.
    Blackstock, A.W., et al. Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) three-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): preliminary report of Cancer and Leukemia Group B (CALGB) 30105. J Clin Oncol 2006 ASCO Annu Mtg Proc Part I 2006. 24(18S):7042.Google Scholar
  245. 245.
    O’Reilly, M. Radiation combined with antiangiogenic and anti-vascular agents. Semin Radiat Oncol 2006. 16:45–50.PubMedCrossRefGoogle Scholar
  246. 246.
    Spiro, S.G., et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004. 59:828–836.PubMedCrossRefGoogle Scholar
  247. 247.
    Chu, Q., et al. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005. 50:355–374.PubMedCrossRefGoogle Scholar
  248. 248.
    Le Chevalier, T., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005. 47:69–80.PubMedCrossRefGoogle Scholar
  249. 249.
    Smit, E.F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975 10.1200/JCO.2003.03.195. J Clin Oncol 2003. 21:3909–3917.PubMedCrossRefGoogle Scholar
  250. 250.
    Schiller, J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer 10.1056/NEJMoaOl 1954. N Engl J Med 2002. 346:92–98.PubMedCrossRefGoogle Scholar
  251. 251.
    Fossella, F., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group 10.1200/JCO.2003.12.046. J Clin Oncol 2003. 21:3016–3024.PubMedCrossRefGoogle Scholar
  252. 252.
    Kelly, K., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001. 19:3210–3218.PubMedGoogle Scholar
  253. 253.
    Scagliotti, G.V., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer 10.1200/JCO.2002.02.068. J Clin Oncol 2002. 20:4285–4291.PubMedCrossRefGoogle Scholar
  254. 254.
    Pfister, D.G., et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: update 2003 10.1200/JCO.2004.09.053. J Clin Oncol 2004. 22:330–353.PubMedCrossRefGoogle Scholar
  255. 255.
    Westeel, V., et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer 10.1093/jnci/dji096. J Natl Cancer Inst 2005. 97:499–506.PubMedCrossRefGoogle Scholar
  256. 256.
    Smith, I.E., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001. 19:1336–1343.PubMedGoogle Scholar
  257. 257.
    Socinski, M.A., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer 10.1200/JCO.20.5.1335. J Clin Oncol 2002. 20:1335–1343.PubMedCrossRefGoogle Scholar
  258. 258.
    Gatzemeier, U., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004. 22:14S [abstract 7010].Google Scholar
  259. 259.
    Herbst, R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2 10.1200/JCO.2004.07.215. J Clin Oncol 2004. 22:785–794.PubMedCrossRefGoogle Scholar
  260. 260.
    Herbst, R.S., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer 10.1200/JCO.2005.02.840. J Clin Oncol 2005. 23:5892–5899.PubMedCrossRefGoogle Scholar
  261. 261.
    Giaccone, G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1 10.1200/JCO.2004.08.001. J Clin Oncol 2004. 22:777–784.PubMedCrossRefGoogle Scholar
  262. 262.
    Sandler, A.B., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial— E4599. J Clin Oncol 2005 ASCO Annu Mtg Proc 2005. 23(16S), part I of II (June 1 supplement):4.Google Scholar
  263. 263.
    Shepherd, F.A., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000. 18:2095–2103.PubMedGoogle Scholar
  264. 264.
    Dancey, J., et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004. 43:183–194.PubMedCrossRefGoogle Scholar
  265. 265.
    Fossella, F.V., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000. 18:2354–2362.PubMedGoogle Scholar
  266. 266.
    Hanna, N., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy 10.1200/JCO.2004.08.163. J Clin Oncol 2004. 22:1589–1597.PubMedCrossRefGoogle Scholar
  267. 267.
    Shepherd, F.A., et al. Erlotinib in previously treated non-small-cell lung cancer 10.1056/NEJMoa050753. N Engl J Med 2005. 353:123–132.PubMedCrossRefGoogle Scholar
  268. 268.
    Lilenbaum, R.C., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005. 23:190–196.PubMedCrossRefGoogle Scholar
  269. 269.
    Langer, C.J., et al. O-52 ECOG 1599: randomized phase II study of paclitaxel/carboplatin versus cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. Lung Cancer 2003. 41(suppl. 2):S18.CrossRefGoogle Scholar
  270. 270.
    Gridelli, C, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel 10.1093/annonc/mdh087. Ann Oncol 2004. 15:419–426.PubMedCrossRefGoogle Scholar
  271. 271.
    Kelly, K., et al. Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001. 20:329a [abstract 1313].Google Scholar
  272. 272.
    Ramalingam, S., et al. Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin: sub-analysis of a randomized trial. Proc Am Soc Clin Oncol 2003. 22:670 [abstract 2693].Google Scholar
  273. 273.
    Langer, C.J., et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 years) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 2003. 22:639 [abstract 2571].Google Scholar
  274. 274.
    Rocha Lima, C.M.S., et al. Therapy choices among older patients with lung carcinoma. Cancer 2002. 94:181–187.PubMedCrossRefGoogle Scholar
  275. 275.
    Kosty, M.P., et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994. 12:1113–1120.PubMedGoogle Scholar
  276. 276.
    Langer, C.J., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial 10.1093/jnci/94.3.173. J Natl Cancer Inst 2002. 94:173–181.PubMedGoogle Scholar
  277. 277.
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival in elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999. 91:66–72.CrossRefGoogle Scholar
  278. 278.
    Gridelli, C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase in randomized trial 10.1093/jnci/95.5.362. J Natl Cancer Inst 2003. 95:362–372.PubMedCrossRefGoogle Scholar
  279. 279.
    Detterbeck, F.C., M.S. Bleiweis, and M.G. Ewend. Surgical treatment of stage IV non-small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:326–338.Google Scholar
  280. 280.
    Wronski, M., et al. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995. 83:605–616.PubMedGoogle Scholar
  281. 281.
    Vecht, C.J., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993. 33:583–590.PubMedCrossRefGoogle Scholar
  282. 282.
    Mintz, A.H., et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996. 78:1470–1476.PubMedCrossRefGoogle Scholar
  283. 283.
    Patchell, R.A., et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005. 366:643–648.PubMedCrossRefGoogle Scholar
  284. 284.
    American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.Google Scholar
  285. 285.
    Morris, D.E., M.A. Socinski, and F.C. Detterbeck. Limited stage small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck, et al., eds. Philadelphia: Saunders; 2001:341–359.Google Scholar
  286. 286.
    Warde, P., and D. Payne. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992. 10:890–895.PubMedGoogle Scholar
  287. 287.
    Pignon, J.P., R. Arriagada, and D.C. Ihde. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992. 327:1618–1624.PubMedGoogle Scholar
  288. 288.
    Bogart, J., J.E. Herndon, 2nd, A.P. Lyss, et al. 70Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004. 59:460.PubMedGoogle Scholar
  289. 289.
    Fried, D., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004. 22:4785–4793.CrossRefGoogle Scholar
  290. 290.
    Turrisi, A., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999. 340:265–271.PubMedCrossRefGoogle Scholar
  291. 291.
    Takada M., F. M., M. Kawahara, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 2002. 20:3054–3060.PubMedCrossRefGoogle Scholar
  292. 292.
    Sundstrom, S., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002. 20:4665.PubMedCrossRefGoogle Scholar
  293. 293.
    Mascaux, C, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. European Lung Cancer Working Party (ELCWP). Lung Cancer 2000. 30:23–36.PubMedCrossRefGoogle Scholar
  294. 294.
    Arriagada, R., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995. 87:183–190.PubMedCrossRefGoogle Scholar
  295. 295.
    Gregor, A., et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997. 33:1717–1719.CrossRefGoogle Scholar
  296. 296.
    Auperin, A., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999. 341:476–484.PubMedCrossRefGoogle Scholar
  297. 297.
    Gillenwater, H.H., and M.A. Socinski. Extensive stage small cell lung cancer, in Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician, F.C. Detterbeck et al., eds. Philadelphia: Saunders; 2001:360–375.Google Scholar
  298. 298.
    Murray, N., et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an inter-group study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999. 17:2300.PubMedGoogle Scholar
  299. 299.
    Loehrer, P.J., et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995. 13:2594–2599.PubMedGoogle Scholar
  300. 300.
    Niell, H.B., et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 10.1200/JCO.2005.09.071. J Clin Oncol 2005. 23:3752–3759.PubMedCrossRefGoogle Scholar
  301. 301.
    Sculier, J.P., M. Paesmans, and J. Lecomte. A three-arm phase in randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001. 85:1444–1451.PubMedCrossRefGoogle Scholar
  302. 302.
    Thatcher, N., et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council Multicenter Randomized LU21 Trial 10.1200/JCO.2004.00.9969. J Clin Oncol 2005. 23:8371–8379.PubMedCrossRefGoogle Scholar
  303. 303.
    Noda, K., Nishiwaki, Y, Kawahara, M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002. 346:85.PubMedCrossRefGoogle Scholar
  304. 304.
    Hanna, N., L. Einhorn, A. Sandler, et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2005. 23:622s.Google Scholar
  305. 305.
    von Pawel, J., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999. 17:658–667.Google Scholar
  306. 306.
    Lad, T., et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994. 106(suppl):320S–323S.PubMedCrossRefGoogle Scholar
  307. 307.
    Landis, S.H., et al. Cancer statistics 1999. CA-Cancer J Clinicians 1999. 49:8–31.CrossRefGoogle Scholar
  308. 308.
    AJCC Cancer Stagina Manual, 6th ed. New York: Springer-Verlag; 2002. www.springer.ny.com.Google Scholar
  309. 309.
    Weisenburger, T.H., M. Gail, and The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986. 315:1377–1381.Google Scholar
  310. 310.
    Mayer, R., et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 1997. 112:954–959.PubMedCrossRefGoogle Scholar
  311. 311.
    Van Houtte, P., et al. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980. 6:983–986.PubMedGoogle Scholar
  312. 312.
    Lafitte, J.J., et al. Postresection irradiation for T2 NO MO non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996. 62:830–834.PubMedCrossRefGoogle Scholar
  313. 313.
    Debevec, M., et al. Postoperative radiotherapy for radically resected N2 non-small-cell cancer (NSCLC): randomised clinical study 1988–1992. Lung Cancer 1996. 14:99–107.PubMedCrossRefGoogle Scholar
  314. 314.
    Arriagada, R., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004. 350:351–360.PubMedCrossRefGoogle Scholar
  315. 315.
    Scagliotti, G.V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003. 95:1453–1461.PubMedGoogle Scholar
  316. 316.
    Waller, D., et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting [abstract]. Proc ASCO 2003. 22:632.Google Scholar
  317. 317.
    Keller, S.M., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000. 343:1217–1222.PubMedCrossRefGoogle Scholar
  318. 318.
    Dautzenberg, B., et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma: a randomized trial of 267 patients. Cancer 1995. 76:779–786.PubMedCrossRefGoogle Scholar
  319. 319.
    Imaizumi, M., et al., for the Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995. 21:69–77.CrossRefGoogle Scholar
  320. 320.
    Feld, R., et al. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer (LCSG 801). J Natl Cancer Inst 1993. 85:299–306.PubMedCrossRefGoogle Scholar
  321. 321.
    Wada, H., et al., and the West Japan Study Group for Lung Cancer Surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (cisplatin + mitomycin C) and UFT (uracil + tegaful) in resected stage I–II NSCLC (non-small cell lung cancer): a randomized clinical trial. Eur J Cardiothorac Surg 1999. 15:438–443.PubMedCrossRefGoogle Scholar
  322. 322.
    Wada, H., et al. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996. 14:1048–1054.PubMedGoogle Scholar
  323. 323.
    Ohta, M., et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg 1993. 106:703–708.PubMedGoogle Scholar
  324. 324.
    Lad, T., et al. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988. 6:9–17.Google Scholar
  325. 325.
    Wolf, M., et al. Randomized phase III trial of adjuvant radiotherapy versus adjuvant chemotherapy followed by radiotherapy in patients with N2 positive non small cell lung cancer (NSCLC) [abstract]. Proc ASCO 2001. 20:31.Google Scholar
  326. 326.
    Holmes, E.C., et al. for the Lung Cancer Study Group, Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986. 4:710–715.PubMedGoogle Scholar
  327. 327.
    Holmes, E.C. Postoperative chemotherapy for non-small-cell lung cancer. Chest 1993. 103:30S–34S.PubMedCrossRefGoogle Scholar
  328. 328.
    Tada, H., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004. 43: 167–173.PubMedCrossRefGoogle Scholar
  329. 329.
    Niiranen, A., et al. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J Clin Oncol 1992. 10:1927–1932.PubMedGoogle Scholar
  330. 330.
    Imaizumi, M. A randomized trial of postoperative adjuvant chemotherapy for p-stage I non-small cell lung cancer (fourth cooperative study) [abstract]. Lung Cancer 2003. 41(suppl 2): S54.CrossRefGoogle Scholar
  331. 331.
    Tada, H., et al. Randomized study of adjuvant chemotherapy for completely resected non-small cell lung cancer: lack of prognostic significance in DNA ploidy pattern at adjuvant setting [abstract]. Proc Am Soc Clin Oncol 2002. 21:313a.Google Scholar
  332. 332.
    Ichinose, Y., et al. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and postrecurrent survival. J Surg Oncol 1991. 46:15–20.PubMedCrossRefGoogle Scholar
  333. 333.
    Pisters, K.M.W., et al. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. J Surg Oncol 1994. 56:236–241.PubMedCrossRefGoogle Scholar
  334. 334.
    Xu, G., T. Rong, and P. Lin. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 2000. 113:617–620.Google Scholar
  335. 335.
    Kimura, H., and Y. Yamaguchi. Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer. Lung Cancer 1996. 14:301–314.PubMedCrossRefGoogle Scholar
  336. 336.
    Mineo, T.C., et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001. 20:378–384.PubMedCrossRefGoogle Scholar
  337. 337.
    Park, J.H., et al. Postoperative adjuvant therapy for stage II non-small-cell lung cancer. Ann Thorac Surg 1999. 68:1821–1826.PubMedCrossRefGoogle Scholar
  338. 338.
    Kato, H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004. 350:1713–1721.PubMedCrossRefGoogle Scholar
  339. 339.
    Nakagawa, M., et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the fourth study 10.1093/annonc/mdi008. Ann Oncol 2005. 16:75–80.PubMedCrossRefGoogle Scholar
  340. 340.
    Endo, C., et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003. 40:181–186.PubMedCrossRefGoogle Scholar
  341. 341.
    Vogt-Moykopf, I., et al. Bronchoplastic techniques for lung resection, in Glenn’s Thoracic and Cardiovascular Surgery, G.A. Baue et al, eds. East Norwalk, CT: Appleton-Lange; 1991:403–417.Google Scholar
  342. 342.
    Dartevelle, P.G. Extended operations for the treatment of lung cancer. Ann Thorac Surg 1997. 63:12–19.PubMedCrossRefGoogle Scholar
  343. 343.
    Deslauriers, J., M. Beaulieu, and A. McClish. Tracheal sleeve pneumonectomy, in General Thoracic Surgery, Shields TW, ed. Philadelphia: Lea and Febiger; 1989:382–387.Google Scholar
  344. 344.
    Mathisen, D.J., and H.C. Grillo. Carinal resection for bronchogenic cancer. J Thorac Cardiovasc Surg 1991. 102:16–23.PubMedGoogle Scholar
  345. 345.
    Jensik, R.J., et al. Survival in patients undergoing tracheal sleeve pneumonectomy for bronchogenic carcinoma. J Thorac Cardiovasc Surg 1982. 84:489–496.PubMedGoogle Scholar
  346. 346.
    Maeda, M., et al. Operative approaches for left-sided carinoplasty. Ann Thorac Surg 1993. 56:441–446.PubMedCrossRefGoogle Scholar
  347. 347.
    Roviaro, G.C., F. Varoli, and C. Rebuffat. Tracheal sleeve pneumonectomy for bronchogenic carcinoma. J Thorac Cardiovasc Surg 1994. 107:13–18.PubMedGoogle Scholar
  348. 348.
    Tsuchiya, R., et al. Resection of tracheal carina for lung cancer. J Thorac Cardiovasc Surg 1990. 99:779–787.PubMedGoogle Scholar
  349. 349.
    Mitchell, J.D., et al. Resection for bronchogenic carcinoma involving the carina: long-term results and effect of nodal status on outcome. J Thorac Cardiovasc Surg 2001. 121:465–471.PubMedCrossRefGoogle Scholar
  350. 350.
    Porhanov, V.A., et al. Indications and results of sleeve carinal resection. Eur J Cardiothorac Surg 2002. 22:685–694.PubMedCrossRefGoogle Scholar
  351. 351.
    Regnard, J.-F., et al. Resection for tumors with carinal involvement: technical aspects, results, and prognostic factors. Ann Thorac Surg 2005. 80:1841–1846.PubMedCrossRefGoogle Scholar
  352. 352.
    Fukuse, T., H. Wada, and S. Hitomi. Extended operation for non-small cell lung cancer invading great vessels and left atrium. Eur J Cardiothorac Surg 1997. 11:664–669.PubMedCrossRefGoogle Scholar
  353. 353.
    Thomas, P., et al. Extended operation for lung cancer invading the superior vena cava. Eur J Cardiothorac Surg 1994. 8:177–182.PubMedCrossRefGoogle Scholar
  354. 354.
    Spaggiari, L., et al. Extended resections for bronchogenic carcinoma invading the superior vena cava system. Ann Thorac Surg 2000. 69:233–236.PubMedCrossRefGoogle Scholar
  355. 355.
    Spaggiari, L., et al. Results of superior vena cava resection for lung cancer. Analysis of prognostic factors. Lung Cancer 2004. 44:339–346.Google Scholar
  356. 356.
    Bernard, A., et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001. 121:1076–1082.PubMedCrossRefGoogle Scholar
  357. 357.
    Burt, M.E., et al. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin N Am, 1987. 67:987–1000.PubMedGoogle Scholar
  358. 358.
    Shirakusa, T., and M. Kimura. Partial atrial resection in advanced lung carcinoma with and without cardiopulmonary bypass. Thorax 1991. 46:484–487.PubMedCrossRefGoogle Scholar
  359. 359.
    Sellman, M., A. Henze, and A. Peterffy. Extended intrathoracic resection for lung cancer: follow-up of 49 cases. Scand J Thorac Cardiovasc Surg 1987. 21:69–72.PubMedGoogle Scholar
  360. 360.
    Ratto, G.B., et al. Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. Ann Thorac Surg 2004. 78:234–237.PubMedCrossRefGoogle Scholar
  361. 361.
    DeMeester, T.R., et al. Management of tumor adherent to the vertebral column. J Thorac Cardiovasc Surg 1989. 97:373–378.PubMedGoogle Scholar
  362. 362.
    Grunenwald, D.H., et al. Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg 2002. 123:271–279.PubMedCrossRefGoogle Scholar
  363. 363.
    Gandhi, S., et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg 1999. 68:1778–1785.PubMedCrossRefGoogle Scholar
  364. 364.
    Ohta, M., et al. Surgical resection for lung cancer with infiltration of the thoracic aorta. J Thorac Cardiovasc Surg 2005. 129:804–808.PubMedCrossRefGoogle Scholar
  365. 365.
    Shiraishi, T., et al. Extended resection of T4 lung cancer with invasion of the aorta: is it justified? Thorac Cardiovasc Surg 2005:375–379.Google Scholar
  366. 366.
    Sause, W.T., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995. 87:198–205.PubMedCrossRefGoogle Scholar
  367. 367.
    Cullen, M.H., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999. 17:3188–3194.PubMedGoogle Scholar
  368. 368.
    Le Chevalier, T., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991. 83:417–423.PubMedCrossRefGoogle Scholar
  369. 369.
    Le Chevalier, T., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst, 1992. 84:58.PubMedCrossRefGoogle Scholar
  370. 370.
    Mattson, K., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988. 24:477–482.PubMedCrossRefGoogle Scholar
  371. 371.
    Kim, T.-Y.M.D.Y., H. Sung Hyun, S.H. Lee, et al. A phase HI randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 2002. 25:238–243.PubMedCrossRefGoogle Scholar
  372. 372.
    Gregor, A., et al. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst 1993. 85:997–999.PubMedCrossRefGoogle Scholar
  373. 373.
    Planting, A., et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer: An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996. 7:139–144.PubMedGoogle Scholar
  374. 374.
    Crino, L., et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993. 4:847–851.PubMedGoogle Scholar
  375. 375.
    Van Houtte, P., et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer: a randomized study, in Treatment Modalities in Lung Cancer: Antibiotic Chemotherapy, R. Arriagada, ed. Basel: Karger; 1988:131–137.Google Scholar
  376. 376.
    Schaake-Koning, C., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992. 326:524–530.PubMedGoogle Scholar
  377. 377.
    Ansari, R., et al. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non small cell lung cancer (NSCLC): a Hoosier Oncology Group (HOG) protocol. Proc ASCO 1991. 10:241.Google Scholar
  378. 378.
    Blanke, C., et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995. 13:1425–1429.PubMedGoogle Scholar
  379. 379.
    Cakir, S., and I. Egehan. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004. 43:309–316.PubMedCrossRefGoogle Scholar
  380. 380.
    Trovo, M.G., et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiation Oncol Biol Phys 1992. 24:11–15.Google Scholar
  381. 381.
    Groen, H.J.M., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study 10.1093/annonc/mdhl00. Ann Oncol 2004. 15:427–432.PubMedCrossRefGoogle Scholar
  382. 382.
    Jeremic, B., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995. 13:452–458.PubMedGoogle Scholar
  383. 383.
    Soresi, E., et al. A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1988. 15:20–25.PubMedGoogle Scholar
  384. 384.
    Fournel, P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study 10.1200/JCO.2005.03.070. J Clin Oncol 2005. 23:5910–5917.PubMedCrossRefGoogle Scholar
  385. 385.
    Belani, C.P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol 10.1200/JCO.2005.55.405. J Clin Oncol 2005. 23:5883–5891.PubMedCrossRefGoogle Scholar
  386. 386.
    Zatloukal, P., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. 2004. 46:87–98.Google Scholar
  387. 387.
    Thongprasert, S., et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999. 24:17–24.PubMedCrossRefGoogle Scholar
  388. 388.
    Woods, R.L., et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990. 61:608–611.PubMedGoogle Scholar
  389. 389.
    Rapp, E., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988. 6:633–641.PubMedGoogle Scholar
  390. 390.
    Cellerino, R., et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991. 9:1453–1461.PubMedGoogle Scholar
  391. 391.
    Cartel, G., et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993. 85:794–800.CrossRefGoogle Scholar
  392. 392.
    Kaasa, S., et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991. 67:2443–2447.PubMedCrossRefGoogle Scholar
  393. 393.
    Ganz, P.A., et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 1989. 63:1271–1278.PubMedCrossRefGoogle Scholar
  394. 394.
    Helsing, M., et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998. 34:1036–1044.PubMedCrossRefGoogle Scholar
  395. 395.
    Anderson, H., et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. U.K. NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000. 83:447–453.PubMedCrossRefGoogle Scholar
  396. 396.
    Roszkowski, K., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000. 27:145–157.PubMedCrossRefGoogle Scholar
  397. 397.
    Ranson, M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer 10.1093/jnci/92.13.1074. J Natl Cancer Inst 2000. 92:1074–1080.PubMedCrossRefGoogle Scholar
  398. 398.
    Frasci, G., et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001. 34(suppl. 4):65–69.CrossRefGoogle Scholar
  399. 399.
    Cormier, Y., et al. Benefits of poly chemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982. 50:845–849.PubMedCrossRefGoogle Scholar
  400. 400.
    Kubota, K., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group 10.1200/JCO.2004.06.114. J Clin Oncol 2004. 22:254–261.PubMedCrossRefGoogle Scholar
  401. 401.
    Cornelia, P., et al. Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine versus either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer. A Southern Italy Cooperative Oncology Group Study. Clin Lung Cancer 2000. 1:202–207; discussion 208.CrossRefGoogle Scholar
  402. 402.
    Brodin, O., and E. Nou. Patients with non-resectable squamous cell carcinoma of the lung: a prospective, randomized study. Lung Cancer 1991. 75:165.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Frank C. Detterbeck
    • 1
    • 2
  • Scott N. Gettinger
    • 3
  • Mark A. Socinski
    • 4
  1. 1.Department Thoracic OncologyYale Cancer Center, Yale-New Haven HospitalNew HavenUSA
  2. 2.Department for Clinical AffairsYale Cancer Center, Yale-New Haven HospitalNew HavenUSA
  3. 3.Department of MedicineYale Medical OncologyNew HavenUSA
  4. 4.Department of Medicine, Lineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel HillUSA

Personalised recommendations